Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Innocoll downgrade details — to Hold at Stifel; tgt lowered to $2 (1.87)Stifel downgrades INNL to Hold from Buy and lowers their tgt to $2 from $9. Yesterday, INNL reported results for 4Q16 with an update regarding its Type-A meeting held with FDA in February over requirements for Xaracoll's NDA resubmission. The company proposed conducting an additional PK study and several short-term non-clinical studies, which would delay the resubmission of its NDA to the end of 2017, pending agreement by FDA on the studies. Despite this proposed path forward, in light of its 4Q16 cash of $15.8mn, INNL does not have sufficient runway to complete these regulatory requirements. As a result, the company is in discussions that may or may not lead to a firm offer for the company. <strong>At this point, firm believes INNL needs to find strategic alternatives, but they cannot be certain of its consummation.</strong></td> </tr></table>"